About Bortezomib API
Therapeutic Category Oncology
CAS Number
179324-69-7
API Technology
Synthetic
Dose Form
Injectable
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, EUDMF, Canada DMF, Russia DMF
Mechanism of Action
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.
Indication
VELCADE is a proteasome inhibitor indicated for:
- Treatment of patients with multiple myeloma
- Treatment of patients with mantle cell lymphoma
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Capivasertib
Oncology
Abiraterone Acetate
Oncology
Azacitidine
Oncology
Cabozantinib Hydrochloride
Oncology
Bortezomib
Oncology
Cabazitaxel
Oncology
Cabozantinib S-Malate
Oncology
Capecitabine
Oncology
Carfilzomib
Oncology
Decitabine
Oncology
Deucravacitinib
Oncology
Eribulin Mesylate
Oncology
Apalutamide (Amorphous & Form B)
Oncology
Bendamustine Hydrochloride
Oncology
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.